Brain & cognitive performance
Semax vs Omberacetam (Noopept)
Both have limited older human literature but different molecular classes, routes and populations; neither has modern large healthy-cognition evidence.
At a glance
Semax
Omberacetam (Noopept)
Human evidence
Older regional stroke and rehabilitation studies report neurological/functional signals and BDNF changes, but this evidence does not establish healthy-person cognitive enhancement.
Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified.
Research focus
Stroke/neuroprotection and cognitive research
Post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic
Regulatory status
Not FDA/EMA-approved; US compounding status has been under FDA review.
FDA substance records identify omberacetam/Noopept but explicitly note that UNII listing does not imply regulatory review or approval. Regulatory status varies internationally.
Route / formulation
Do not convert regional clinical use into a general cognitive-enhancement claim.
Most clinical literature concerns oral use in neurologic patients; it should not be extrapolated to other formulations or healthy-user 'nootropic' protocols.
No robust direct head-to-head trial identified Both have limited older human literature but different molecular classes, routes and populations; neither has modern large healthy-cognition evidence.